Market Intelligence, Clinical Progress, and High-Purity Reagents for Intracellular Trafficking, Antiviral & Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ARFGEF2 (BIG2) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ARFGEF2 Sec7 Domain & Full-Length Recombinant Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 or E. coli expression available. | View ARFGEF2 Products |
| Gene Delivery | ARFGEF2 Lentivirus Premade Particles. Full-length ORF for stable cell lines. HEK293 Expressed (Native Glycosylation). Suitable for ARF1 activation and trafficking assays. | View ARFGEF2 Products |
| Benchmark Ab | Anti-ARFGEF2 Recombinant Antibody. Research-grade positive control for Western blot, IP, and IHC. | View ARFGEF2 Products |
| Validator | ARFGEF2 siRNA Set (3 Unique Targets). Sequence-verified knockdown reagents for specificity verification. | View ARFGEF2 Products |
| Substrate Partner | ARF1 Recombinant Protein (GTP-locked & WT). Required for GEF activity assays. High purity. | View ARF1 Products |
| Pathway Paralog | ARFGEF1 (BIG1) Protein. Counter-screening for selectivity vs BIG1. Strictly verified by mass spectrometry. | View ARFGEF1 Products |
| Related Target | EGFR. Oncogenic receptor tyrosine kinase regulated by ARFGEF2 trafficking; key readout in GBM models. | View EGFR Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Cyno/Mouse Evaluation | Human / Mouse / Cyno ARFGEF2 ortholog proteins available with >95% purity and sequence verification. |
| Intracellular Domain Targeting | High-purity Sec7 domain recombinant proteins available for precise SPR/BLI binding assays. |
| GEF Enzymatic Activity (GTP/GDP Exchange) | Purified ARFGEF2 GEF Domain + ARF1 Substrate Pair. Sequence Verified. >95% purity. |
| Paralog Selectivity (BIG1 vs BIG2) | Homolog Panel: ARFGEF1 & ARFGEF2 proteins strictly verified by mass spec for selectivity screening. |
| Lack of Mechanistic Controls | Catalytic-dead Sec7 mutant and Benchmark Antibodies included for assay validation. |
| False Positives / Off-target Effects | Validated siRNA included for target-specificity checks in cellular assays. |
| Cell-based Trafficking & Activation Validation | HEK293-expressed Lentivirus ORF particles for stable ARFGEF2 expression and functional readouts. |
Live ARFGEF2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
ARFGEF2 (BIG2) is a guanine nucleotide exchange factor (GEF) that activates ARF1/ARF3 to regulate Golgi-vesicle trafficking. The therapeutic landscape is transitioning from academic discovery to early drug development, driven by dual opportunities in oncology and antiviral host-directed therapy. In cancer, ARFGEF2 mediates oncogenic receptor trafficking (e.g., EGFR) and shows synthetic lethality in glioblastoma and pancreatic cancer. In virology, it is an essential host factor for Dengue, Zika, and SARS-CoV-2. The next wave of R&D focuses on selective Sec7 domain allosteric modulation and targeted protein degradation (PROTAC) to avoid systemic toxicity from non-specific Golgi disruption. Key challenges include achieving paralog selectivity over ARFGEF1 (BIG1) and ensuring intracellular delivery.
Key Mutations & Clinical Relevance
ARFGEF2 mutations are linked to periventricular nodular heterotopia type 2 (PVNH2) and have been reported in cancer. Notable variants (per UniProt Q9Y6D5):
- rs28937880 (in PVNH2, uncertain significance) – Located in the Sec7 domain, may impact GEF activity.
- rs6063343 – A common variant with unknown significance.
- Somatic mutation – Found in a breast cancer sample, suggesting a potential role in tumorigenesis.
These mutations underscore the need for disease-relevant recombinant proteins and functional assays.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Academic Consortia, Emerging Biotech | Glioblastoma, Pancreatic Cancer, Broad-Spectrum Antiviral | GEF Activity Assay (Need purified ARFGEF2 + ARF1 substrate pair) |
| PROTAC / Degrader | Preclinical Pharma | Oncology (Solid Tumors) | Ternary Complex Validation (Need purified Sec7 domains) |
| siRNA / RNAi | Oligonucleotide Developers, Functional Genomics | Synthetic Lethality Combinations, Host-directed therapy | Knockdown Validation (Need validated siRNA sets) |
| Chemical Probes | Structural Biology Groups | Mechanism of Action Studies | Co-crystal Screening (Need high-concentration stable protein) |
| Phenotypic Screen | High-Content Screening Labs | Golgi Trafficking Disorders | Cell-based Assay (Need Lentivirus for stable overexpression lines) |